Table of Contents
Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up reaching 15 months total. The trial design included both a blinded treatment phase and a randomized withdrawal phase, providing a rigorous assessment of both efficacy and what happens when treatment stops. Results from this scale of study carry meaningful weight for clinicians considering cannabis-based options for patients who have not responded adequately to conventional therapies.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
What This Study Teaches Us
A full-spectrum cannabis extract (VER-01) reduced chronic low back pain by about 0.6 points on a 10-point scale more than placebo over 12 weeks, and further pain relief accumulated over 6 months of open-label use. For patients with neuropathic features, the extract also reduced neuropathic pain symptoms significantly more than placebo.
Why This Matters Clinically
Chronic low back pain is endemic and current drugs (NSAIDs, opioids, muscle relaxants) have limited efficacy and real risks. This phase 3 trial, published in Nature Medicine, provides the strongest evidence to date that a defined cannabis extract has measurable pain benefit in a large, controlled setting, giving clinicians and patients a documented alternative worth discussing for refractory cases.
Study Snapshot
| Study Design | Multicenter, randomized, placebo-controlled phase 3 trial with 12-week double-blind phase (A), 6-month open-label extension (B), and randomized withdrawal phase (D) |
| Population | 820 adults with chronic low back pain (394 VER-01, 426 placebo); subgroup analysis for neuropathic pain component (PainDETECT > 18) |
| Intervention | VER-01, a full-spectrum Cannabis sativa extract (DKJ127 strain); dose and frequency not specified in abstract |
| Primary Outcome | Change in numeric rating scale (NRS) pain intensity over 12 weeks; secondary outcome was neuropathic pain symptom inventory (NPSI) score change in neuropathic subgroup |
| Key Result | VER-01 reduced pain by 1.9 NRS points versus 1.3 for placebo (difference 0.6 points, P < 0.001); NPSI reduction favored VER-01 by 7.3 points (P = 0.017); withdrawal phase did not show statistically significant time-to-failure difference but placebo showed greater pain rebound |
Where This Paper Deserves Skepticism
The 0.6-point NRS difference, while statistically significant, sits at the lower end of clinically meaningful thresholds and is substantially smaller than what many patients hope cannabis will deliver. The abstract truncates before reporting adverse event rates, which is a critical omission given that 83.3% of the active group experienced side effects. The withdrawal phase failed its primary endpoint, suggesting effects may not be durable or that dependence patterns could complicate real-world use. Dosing, specific cannabinoid profiles, and THC to CBD ratios are not disclosed, limiting replicability and clinical guidance.
Dr. Caplan’s Take
I read this as encouraging but not transformative. The study design is solid and the journal placement reflects quality, but the effect size is modest and the adverse event burden appears substantial. The neuropathic pain benefit is interesting because cannabis may have mechanistic rationale there, but we’re still seeing marginal gains over placebo in absolute terms. For my patients, this shifts the conversation from no evidence to some evidence, but I’m not recommending it as first-line or as a replacement for guideline-based multimodal care. It becomes a reasonable option to discuss after conventional approaches plateau, with clear expectations about effect magnitude and side effects.
Clinical Bottom Line
VER-01 shows statistically significant but clinically modest pain benefit over placebo in chronic low back pain, with higher adverse event rates in the treatment group. This supports further investigation and patient discussion for refractory cases, but does not yet position cannabis extract as a first-line alternative to current therapies.
| |
Have thoughts on this? Share it: